Skip to main content
. 2023 Jan 19;26(1):46–59. doi: 10.4048/jbc.2023.26.e2

Figure 3. Secondary outcomes. Results are expressed as mean ± standard deviation and as individual datapoints. (A) Change in mean L-Dex scores. (B) Change in mean of HRQoL assessed with the LYMPH-ICF questionnaire ranging from 0 (best) to 100 (worst). (C) Change in mean of HRQoL assessed with the DASH questionnaire ranging from 0 (best) to 100 (worst). (D) Change in mean of HRQoL assessed with the SF-36 questionnaire ranging from 100 (best) to 0 (worst).

Figure 3

L-Dex = lymphedema index; HRQoL = health-related quality of life; LYMPH-ICF = Lymphoedema Functioning, Disability and Heath; DASH = Disability of the Arm Shoulder and Hand; SF-36 = 36-Item Short Form Health Survey.

*p < 0.05 compared to baseline; **p < 0.001 compared to baseline.